ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

High Expression of ACE2 and TMPRSS2 at the Resection Margin Makes Lung Cancer Survivors Susceptible to SARS-CoV-2 With Unfavorable Prognosis

Wang, Qianqian; Li, Liangyu; Qu, Tianyu; Li, Jie; Wu, Lingxiang; Li, Kening; Wang, Ziyu; Zhu, Mengyan; Huang, Bin; Wu, Wei; Wu, Min; Ding, Rong; Zhang, Zhihong; Wang, Qianghu; Xia, Xinyi*; Li, Pengping*; Zhang, Zhi; Guo, Renhua*南方医科大学; 南京大学; 1
Frontiers in Oncology2021-5-21DOI: 10.3389/fonc.2021.644575
11被引9阅读
引用收藏
分享

摘要

Background @@@ Coronavirus disease 2019 (COVID-19) has rapidly spread worldwide. Systematic analysis of lung cancer survivors at molecular and clinical levels is warranted to understand the disease course and clinical characteristics. @@@ Methods @@@ A single-center, retrospective cohort study was conducted in 65 patients with COVID-19 from Wuhan Huoshenshan Hospital, of which 13 patients were diagnosed with lung cancer. The study was conducted from February 4 to April 11, 2020. @@@ Results @@@ During the course of treatment, lung cancer survivors infected with severe acute respiratory syndrome coronavirus 2 (SARS-COV-2) had shorter median time from symptom onset to hospitalization (P = 0.016) and longer clinical symptom remission time (P = 0.020) than non-cancer individuals. No differences were observed among indicators such as time from symptom onset to hospitalization and symptom remission time between medium-term and short-term survivors. The expression of ACE2 (P = 0.013) and TMPRSS2 (P <0.001) was elevated in lung cancer survivors as compared with that in non-cancer individuals. @@@ Conclusions @@@ ACE2 and TMPRSS2 levels were higher at resection margins of lung cancer survivors than those in normal tissues of non-cancerous individuals and may serve as factors responsible for the high susceptibility to COVID-19 among lung cancer survivors. Lung cancer patients diagnosed with COVID-19, including medium-term survivors, have worse outcomes than the general population.

学科与关键词

关键词
COVID-19lung cancerACE2single celltmprss2
相关
加载中…
  • High expression of ACE2 and TMPRSS2 and clinical characteristics of COVID-19 in colorectal cancer patients
    Liu, Chao; Wang, Kai; Zhang, Min; Hu, Xiaoyu; Hu, Tian; Liu, Yumei; Hu, Qinyong*; Wu, Shikai*; Yue, Jinbo*npj Precision Oncology, 2021, 5(1): 1.被引 29
  • Association of COVID-19 and Lung Cancer: Short-Term and Long-Term Interactions
    Peng, Ying-Long; Wang, Zi-Yan; Zhong, Ri-Wei; Mei, Shi-Qi; Liu, Jia-Qi; Tang, Li-Bo; Guo, Zhi; Ren, Zi-Rui; Wu, Lv; Deng, Yu; Chen, Zhi-Hong; Zhou, Qing; Xu, Chong-Rui*Cancers, 2024, 16(2): 304.
  • Evaluation and characterization of HSPA5 (GRP78) expression profiles in normal individuals and cancer patients with COVID-19
    Fu, Jiewen; Wei, Chunli; He, Jiayue; Zhang, Lianmei; Zhou, Ju; Balaji, Kyathegowdanadoddi Srinivasa; Shen, Shiyi; Peng, Jiangzhou*; Sharma, Amrish*; Fu, JunjiangInternational Journal of Biological Sciences, 2021, 17(3): 897-910.被引 27
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Oncology
发表日期
2021-05-21
卷期
第 11 卷
页码
644575
DOI
10.3389/fonc.2021.644575
期刊收录
NSL
期刊等级
3区
成果收录
SCIE
资助标注
National Natural Science Foundation of China [NSFC 81972188, 81572893, 81972358, 81959113]; Medical Important Talents [ZDRCA2016024]

作者

  • W

    Wang, Qianqian (第一作者)

  • L

    Li, Liangyu

    nanjing med univ

查看全部 18 位作者收起作者
  • Q

    Qu, Tianyu

    1 · nanjing med univ

  • L

    Li, Jie

    nanjing med univ

  • W

    Wu, Lingxiang

    nanjing med univ

  • L

    Li, Kening

    nanjing med univ

  • W

    Wang, Ziyu

    nanjing med univ

  • Z

    Zhu, Mengyan

    nanjing med univ

  • H

    Huang, Bin

    nanjing med univ

  • W

    Wu, Wei

    nanjing med univ

  • W

    Wu, Min

    nanjing med univ

  • D

    Ding, Rong

    nanjing med univ

  • Z

    Zhang, Zhihong

  • W

    Wang, Qianghu

  • X

    Xia, Xinyi (通讯)

    nanjing univ · southern med univ

  • L

    Li, Pengping (通讯)

    nanjing med univ

  • Z

    Zhang, Zhi

  • G

    Guo, Renhua (通讯)

    1 · nanjing med univ

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417